Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quantitative Magnetic Resonance Spectroscopic Imaging (MRSI) to Predict Early Response to Standard Radiation Therapy (RT)/Temozolomide (TMZ) ± Belinostat Therapy in Newly-Diagnosed Glioblastomas (GBM)

Next Previous
Trial Profile

Quantitative Magnetic Resonance Spectroscopic Imaging (MRSI) to Predict Early Response to Standard Radiation Therapy (RT)/Temozolomide (TMZ) ± Belinostat Therapy in Newly-Diagnosed Glioblastomas (GBM)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belinostat (Primary) ; Temozolomide
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 03 May 2023 Planned End Date changed from 30 Aug 2022 to 15 Aug 2024.
  • 03 May 2023 Planned primary completion date changed from 30 Aug 2022 to 15 Aug 2023.
  • 01 Sep 2021 Planned End Date changed from 6 Sep 2021 to 30 Aug 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top